The DOI matches its Crossref record.
In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
Open accessAbstract
The in vitro activity of the new antifungal drug pneumocandin L-743,872 against 55 isolates of clinically important molds was examined by an adapted macrobroth dilution method for yeasts. Pneumocandin L-743,872 exhibited in vitro antifungal activity against Alternaria sp., Aspergillus flavus, Aspergillus fumigatus, Curvularia lunata, Exophiala jeanselmei, Fonsecaea pedrosoi, Paecilomyces variotii, and Scedosporium apiospermum. The drug appeared to lack significant in vitro inhibitory activity against Fusarium oxysporum, Fusarium solani, Rhizopus arrhizus, Paecilomyces lilacinus, and Scedosporium prolificans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Infections Caused by Scedosporium spp
Cortez, K. J., Roilides, E., Quiroz-Telles, F., Meletiadis, J., Antachopoulos, C., Knudsen, T., Buchanan, W., Milanovich, J., Sutton, D. A., Fothergill, A., et al. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00039-07 · Cited by 786
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Self-citationInfections due to emerging and uncommon medically important fungal pathogens
Walsh, T. J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E., & Anaissie, E. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00839.x · Cited by 601
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Combination Polyene‐Caspofungin Treatment of Rhino‐Orbital‐Cerebral Mucormycosis
Reed, C., Bryant, R., Ibrahim, A. S., Edwards, Jr., Filler, S. G., Goldberg, R., & Spellberg, B. (2008) · Clinical Infectious Diseases · doi:10.1086/589857 · Cited by 494
Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens
De Lucca, A. J., & Walsh, T. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.1 · Cited by 337
Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.57-62.2000 · Cited by 311
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Newer Systemic Antifungal Agents: Pharmacokinetics, Safety and Efficacy
Boucher, H. W., Groll, A. H., Chiou, C. C., & Walsh, T. J. (2004) · Drugs · doi:10.2165/00003495-200464180-00001 · Cited by 305
Uncommon opportunistic fungi: new nosocomial threats
Groll, A. H., & Walsh, T. J. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00005.x · Cited by 305
Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist*
Guarro, J., Kantarcioglu, A. S., Horré, R., Luis Rodriguez-Tudela, J., Cuenca Estrella, M., Berenguer, J., & Sybren De Hoog, G. (2006) · Medical Mycology · doi:10.1080/13693780600752507 · Cited by 297
Saravolatz, L. D., Deresinski, S. C., & Stevens, D. A. (2003) · Clinical Infectious Diseases · doi:10.1086/375080 · Cited by 293
In Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases
Rodriguez-Tudela, J. L., Rodriguez-Tudela, J. L., Berenguer, J., Guarro, J., Kantarcioglu, A. S., Horre, R., Sybren De Hoog, G., & Cuenca-Estrella, M. (2009) · Medical Mycology · doi:10.1080/13693780802524506 · Cited by 269
Kraus, P. R., Fox, D. S., Cox, G. M., & Heitman, J. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03508.x · Cited by 217
Thompson, J. R., Douglas, C. M., Li, W., Jue, C. K., Pramanik, B., Yuan, X., Rude, T. H., Toffaletti, D. L., Perfect, J. R., & Kurtz, M. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.2.444-453.1999 · Cited by 196
Self-citationDel Poeta, M., Cruz, M. C., Cardenas, M. E., Perfect, J. R., & Heitman, J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.739-746.2000 · Cited by 169
Antifungal Resistance Trends Towards the Year 2000: Implications for Therapy and New Approaches
Alexander, B. D., & Perfect, J. R. (1997) · Drugs · doi:10.2165/00003495-199754050-00002 · Cited by 153
Self-citationIkeda, F., Wakai, Y., Matsumoto, S., Maki, K., Watabe, E., Tawara, S., Goto, T., Watanabe, Y., Matsumoto, F., & Kuwahara, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.614-618.2000 · Cited by 147
“fumigatus and have profound morphological effects, although they do not give MICs for Aspergillus species in a classic broth dilution assay (9, 12, 14, 18).”
BackgroundEchinocandins in antifungal pharmacotherapy
Patil, A., & Majumdar, S. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12780 · Cited by 145
Caspofungin: first approved agent in a new class of antifungals
Johnson, M. D., & Perfect, J. R. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.807 · Cited by 85
Self-citation
Metadata
- Authors
- Del Poeta, M., Schell, W. A., & Perfect, J. R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-08
- Volume
- 41
- Issue
- 8
- Pages
- 1835-1836
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2102546193
- Cited by
- 164
- References
- 0
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.